C4 Therapeutics : CFT8919 Pre-Clinical Data

CFT8919 Pre-Clinical Data Investor Call

June 7, 2021

Forward-looking Statements and Intellectual Property

Forward-looking Statements

The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.'s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.

Intellectual Property

C4 Therapeutics, Inc. owns various registered and unregistered trademarks in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the symbols ® and ™, but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

© 2021 C4 Therapeutics, Inc.

2

Today's Agenda

Topic	Participants
Introductions	Kendra Adams, SVP Communications &
	Investor Relations
Opening Remarks	Andrew Hirsch, President and CEO
CFT8919 Pre-clinical Data Overview	Adam Crystal, M.D., Ph.D., CMO
Q&A Session	Andrew Hirsch, Adam Crystal and Stew
	Fisher, CSO

© 2021 C4 Therapeutics, Inc.

3

What You Will Hear Today

• CFT8919 is an orally bioavailable, selective, allosteric degrader of EGFR L858R
• Active in vitro and in vivo in models with secondary EGFR mutations
• Demonstrates intracranial activity indicating potential to prevent or treat brain metastases in patients with EGFR L858R-driven tumors
• 25-45%of mutant EGFR NSCLC is driven by L858R activating mutation; these patients are not adequately addressed with current EGFR therapies
• Pre-clinicaldata suggests CFT8919 has path to registration in EGFR patients who develop resistance to osimertinib

Sources: Li, K et al. Oncol Rep 37, 1347-1358 (2017);Jin Y. et al. Scientific Reports 6:31636 (2016); Soria, J.-C. et al. NEJM 378, 113-125 (2018)

© 2021 C4 Therapeutics, Inc.

4

TORPEDO Platform Has Delivered a Robust Degrader Pipeline; Four Clinical Programs Expected by End of 2022

Target	Indication(s)	Discovery	Preclinical	Clinical	Ownership
IKZF1/3 (CFT7455)	Multiple Myeloma & Lymphoma
BRD9 (CFT8634)	Synovial Sarcoma & SMARCB1 Deleted
Tumors
EGFR (CFT8919)	Drug-Resistant EGFR+ NSCLC
BRAF V600E	Drug-Resistant BRAF mutant
Tumors
RET	Drug-ResistantRET-Altered Tumors
Transcriptional Control	Undisclosed Solid Tumors
Cancer Signaling	Undisclosed Cancers
Transcriptional Control	Undisclosed Liquid Tumors
Cancer Signaling	Undisclosed Solid Tumors

Nine Additional Undisclosed Collaborator Programs in Discovery

© 2021 C4 Therapeutics, Inc.

5